ArticleArthritis care & research2026
Polypharmacy in Adults With Systemic Lupus Erythematosus.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conditions identified by common comprehensive geriatric assessment measures and subsequent acute care among adults with SLE.Lupus science & medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveEstimates of polypharmacy among US adults with systemic lupus erythematosus (SLE)-a relatively young and disproportionately minoritized population-remain sparse. We sought to estimate the prevalence of polypharmacy in SLE and identify the most common medications used.
methodsFor this cross-sectional study, participants were recruited from a population-based cohort of adults with validated SLE in Atlanta, Georgia. Prescription and over-the-counter (OTC) medications were self-reported at the study visit. Polypharmacy was defined as five or more prescription or OTC medications. Estimates of polypharmacy prevalence by key sociodemographic and SLE-related participant characteristics were obtained using crude logistic regression and postestimation marginals.
resultsMore than half (56.3%) of participants (n = 451; 15.3% ≥60 years old, 91.8% women, and 81.8% Black) reported polypharmacy. Older age (68.1%, 59.8%, and 43.0% for ages ≥60 years, 40-59 years, and 18-39 years), higher vs lower disease activity (65.8% vs 46.2%) and cumulative SLE-related damage (68.5% vs 42.4%), longer disease duration (62.4% vs 50.0%), and taking three to five vs zero to one immunomodulating medications (79.6% vs 38.0%) were associated with higher age-adjusted prevalence of polypharmacy; prevalence was not statistically significantly different by sex, race, or education. Although hydroxychloroquine (71.4%), glucocorticoids (44.3%), and other immunomodulating drugs (50.3%) were common, polypharmacy was most often driven by other medications, such as antihypertensives (61.9%), nonopioid pain relievers (51.7%), allergy treatments (22.4%), antidepressants (22.2%), and gastric reflux medications (21.7%).
conclusionOur results underscore the need to address the burden of medication regimens in this population through individualized medication optimization strategies that account for prescription and OTC medications used by those with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.